Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDICT: RAPID3 vs CDAI in RA with Cimzia
NCT01255761Phase 4Completed
- Sponsor
- UCB
- Start
- Nov 2010
- Primary completion
- Oct 2012
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of certolizumab pegol in rheumatoid arthritis (RA) (2 arms), sponsored by UCB. Primary endpoints: Response at Week 12 as Assessed by Randomized Tool (CDAI or RAPID3) and Responders at Week 12 Achieving Low Disease Activity (DAS28[ESR] <= 3.2) at Week 52. Started Nov 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01255761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01255761.